- Wantai plans to start a large trial for its nasal spray-based COVID-19 vaccine candidate next month
- the company aims to recruit 40,000 adult participants for the Phase III clinical trial
- adults would be given two doses of the Beijing Wantai vaccine candidate or a placebo vaccine at a two-week interval
- the spray vaccine can trigger specific immune responses in the airways by mimicking the natural infection of a respiratory virus
Chinese vaccine manufacturer “Beijing Wantai Biological Pharmacy Enterprise” plans to start a clinical trial of the vaccine in the form of a nasal spray next month says an article published on Today Online.
Trial for nasal spray-based vaccine candidate
Beijing Wantai Biological Pharmacy Enterprise plans to start a large trial for its nasal spray-based COVID-19 vaccine candidate next month, a clinical trial registration record showed. The company aims to recruit 40,000 adult participants for the Phase III clinical trial, according to an entry posted on the Chinese Clinical Trial Registry on Wednesday.
Potential to carry trial in approved countries
The adults would be given two doses of the Beijing Wantai vaccine candidate or a placebo vaccine at a two-week interval, it said. The record did not specify in how many countries Beijing Wantai will run the trial. But it said an ethics committee in the Philippines had approved the study, clearing some hurdles for potentially carrying out a trial in that country.
How the spray vaccine works
An alternative to the common injection in the arm, the spray vaccine can trigger specific immune responses in the airways by mimicking the natural infection of a respiratory virus. The candidate uses a weakened influenza virus to ferry the genetic information of part of the coronavirus.
Did you subscribe to our daily newsletter?
It’s Free! Click here to Subscribe
Source: Today Online
